Heart Valve Replacement — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Heart valve replacement is a cardiac surgical or transcatheter procedure in which a diseased, stenotic, or regurgitant heart valve — most commonly the aortic or mitral valve — is removed and substituted with a prosthetic valve to restore normal cardiac haemodynamics. Two broad categories of prosthetic valves are in clinical use. Mechanical prostheses (bileaflet tilting disc valves such as St Jude Medical or Carbomedics) are made of carbon and metal alloy, providing lifelong durability, but require permanent anticoagulation with warfarin to prevent thromboembolic events. Bioprosthetic (tissue) valves use porcine (pig) or bovine (cow) pericardial leaflets mounted on a stent, providing excellent haemodynamics without requiring long-term anticoagulation, but with limited durability (typically 15–20 years, shorter in younger patients). The choice between mechanical and biological valves is individualised based on patient age, lifestyle, bleeding risk, and anticoagulation tolerance. A major development is transcatheter aortic valve implantation (TAVI/TAVR) — a catheter-based procedure in which a collapsible bioprosthetic valve is delivered via the femoral artery (or alternative access routes) and deployed across the native diseased aortic valve, eliminating the need for open sternotomy and cardiopulmonary bypass. TAVR has expanded from high-risk and inoperable patients (PARTNER trials) to intermediate-risk patients and, increasingly, low-risk patients younger than 65 in contemporary guidelines.

Heart valve replacement is indicated when valve disease is severe enough to cause symptoms (dyspnoea, angina, syncope) or to threaten cardiac function even in the absence of symptoms. Aortic stenosis (AS) is the most common indication: severe AS (mean gradient >40 mmHg, valve area <1 cm², peak velocity >4 m/s) with symptoms of heart failure, angina, or syncope is a Class I indication for valve replacement. Severe AS with left ventricular ejection fraction below 50%, or very severe AS (gradient >60 mmHg) even without symptoms, is also an indication. Severe aortic regurgitation causing symptoms or progressive LV dilation (LVESD >50 mm or LVEF <55%) is an indication. Severe mitral stenosis (MVA <1.5 cm²) with symptoms refractory to balloon commissurotomy or with anatomy unsuitable for repair is managed by mitral valve replacement. Severe mitral regurgitation causing symptoms, reduced LVEF below 60%, or progressive LV dilation, where mitral repair is not feasible, is treated by replacement. Prosthesis type is selected based on age (mechanical preferred under 60; bioprosthetic preferred over 65–70), preference regarding anticoagulation, planned pregnancy, and comorbid conditions. TAVR is now indicated for all surgical risk groups for aortic valve disease — shared decision-making between the patient and a multidisciplinary heart valve team is mandatory.

Surgical aortic or mitral valve replacement requires median sternotomy (midline chest incision) and establishment of cardiopulmonary bypass (CPB), which takes over the heart and lung function while the heart is arrested with cardioplegia solution. The diseased valve leaflets are excised and the annulus (the fibrous ring) is debrided of calcium. The prosthetic valve is sized, inserted, and secured with multiple sutures around the annular circumference. For mitral replacement, the posterior leaflet and chordal apparatus are preserved where possible to maintain LV geometry and function. CPB is then weaned as the heart restarts. Minimally invasive approaches (ministernotomy or right mini-thoracotomy) reduce surgical trauma with equivalent outcomes. For TAVR: access is via the right femoral artery (TF-TAVR, preferred) or transapical/transaortic/subclavian routes. Under general anaesthesia or conscious sedation, a balloon-expandable (Edwards Sapien) or self-expanding (Medtronic Evolut) bioprosthetic valve is crimped onto a delivery system, advanced retrogradely across the aortic valve under fluoroscopic and echocardiographic guidance, and deployed with precise positioning. Rapid ventricular pacing during deployment reduces cardiac output momentarily for accurate positioning. The procedure takes 1–2 hours; most TAVR patients avoid ICU admission and are discharged in 2–5 days.

The procedure is performed in an appropriately equipped facility by experienced specialist clinicians. Prior to commencement, the patient undergoes pre-procedural assessment including vital signs measurement, review of relevant investigations, and confirmation of informed consent. Intravenous access is established and monitoring equipment including ECG, pulse oximetry, and blood pressure monitoring is applied.

The procedural site is prepared according to aseptic technique standards. Anaesthesia or analgesia is administered as appropriate for the specific procedure and patient needs, ranging from local anaesthesia for minor procedures to regional or general anaesthesia for more complex interventions.

The procedure is performed under direct visualisation or image guidance as appropriate. Key technical steps are executed with attention to anatomical landmarks and patient safety parameters. Haemostasis is achieved and confirmed before completion. Post-procedural assessment includes clinical evaluation of the immediate result, complication surveillance, and documentation of the procedure.

Recovery room monitoring continues until the patient meets defined discharge criteria. Written post-procedural instructions covering activity restrictions, wound care, medication management, and symptoms requiring urgent review are provided before discharge.

Heart valve replacement markedly improves symptoms and survival in patients with severe valvular disease. For severe symptomatic aortic stenosis — median survival of only 2–3 years without intervention once heart failure symptoms appear — surgical AVR reduces mortality risk to near the age-matched general population. TAVR in landmark trials has demonstrated comparable 2-year and 5-year survival to surgical AVR across all risk categories: the PARTNER 3 and Evolut Low Risk trials confirmed non-inferiority of TAVR in low-risk patients. Functional improvement is substantial: 80–90% of patients move from NYHA Class III–IV (severely symptomatic) to Class I–II (minimal or no symptoms) within 3–6 months of valve replacement. For mitral valve disease with heart failure and reduced ejection fraction, valve replacement combined with coronary revascularisation improves LV function by eliminating the volume overload of mitral regurgitation. Mechanical valves provide lifetime durability, eliminating the need for repeat procedures — a major benefit for patients under 60. Modern bioprosthetic valves last 15–20 years in patients over 65, with transcatheter valve-in-valve (ViV-TAVR) technology allowing repeat treatment of structural valve deterioration without repeat open surgery.

Heart valve replacement carries procedural and long-term complication risks. Surgical valve replacement 30-day mortality in low-risk patients is under 2%; in high-risk patients it is 5–10%, justifying the shift to TAVR in this group. Stroke affects 1–3% of surgical valve replacement patients. New-onset atrial fibrillation after surgery is common (25–40%), usually self-limiting within 6–12 weeks. Renal failure requiring dialysis occurs in 1–3%. Wound infection and mediastinitis (sternotomy infection) affect under 1%. Prosthetic valve endocarditis is a serious long-term complication affecting 0.5–1% per year for both mechanical and bioprosthetic valves and requires prolonged IV antibiotics and often repeat surgery. Structural valve deterioration (SVD) of bioprosthetic valves begins accelerating after 10–15 years and eventually necessitates reintervention in patients with long life expectancy. Anticoagulation-related bleeding is the primary long-term risk of mechanical valves — a major haemorrhagic event rate of 1–2% per year with appropriately managed warfarin therapy. TAVR-specific risks include permanent pacemaker requirement (10–20% with self-expanding valves due to conduction system trauma), paravalvular aortic regurgitation (residual leak alongside the prosthesis), and vascular access complications.

After surgical valve replacement, patients spend 24–48 hours in the cardiac intensive care unit for haemodynamic monitoring and ventilator weaning. A drain removes fluid from the pericardial space for 24–48 hours. Ward recovery follows for 5–7 days. Cardiac rehabilitation is recommended starting 4–6 weeks post-operatively, with return to sedentary work at 6–8 weeks and physical labour at 3 months. Sternal precautions — avoid lifting over 5 kg and pushing/pulling for 6–8 weeks — are essential to allow sternotomy healing. After TAVR, most patients mobilise on the day of the procedure and are discharged within 2–5 days; return to normal activity is typically within 2 weeks, with sternal precautions not applicable given the percutaneous access. Anticoagulation management: mechanical valve patients require lifelong warfarin with target INR 2.5–3.5 (aortic) or 3.0–4.0 (mitral); INR monitoring is required monthly when stable. Bioprosthetic surgical valve patients take aspirin and/or low-dose anticoagulation for 3–6 months; TAVR patients typically take aspirin alone or dual antiplatelet therapy for 3–6 months. Regular echocardiographic follow-up at 1 year and then every 3–5 years monitors prosthetic valve function. Antibiotic prophylaxis before dental and certain surgical procedures is required for all prosthetic heart valves.